French biotech firm Hybrigenics said this week that it has incorporated a US-based subsidiary, Hybrigenics Corporation.

To be based in Cambridge, Mass., the subsidiary will focus primarily on Hybrigenics' protein-protein interaction fee-for-service business, and will represent the company for US-based "R&D, regulatory, and business development matters," it said.

Hybrigenics' protein-protein interaction business currently generates more than 30 percent of its total revenues in the US, or roughly €1 million ($1.35 million) per year, the company said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.